Evaluation of the effectiveness of long-acting insulin analogs in patients with type 2 diabetes mellitus
Yükleniyor...
Dosyalar
Tarih
2023
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Springer Heidelberg
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Aim In this study, we aimed to evaluate the effectiveness of long-acting insulin analogs in the treatment of type 2 diabetes mellitus (T2DM) in our clinic. Methods Patients with T2DM who were prescribed long-acting insulin analog therapy in our internal medicine outpatient clinic between November 2017 and December 2019 were included in the study. Patients' age, gender, duration of diabetes, HbA1c values, insulin doses and injections in previous treatment, and fasting blood glucose levels before the initiation of long-acting insulin analog were recorded. Fasting blood glucose levels after the initiation of long-acting insulin analog therapy, HbA1c values, total insulin doses in the new treatment and the number of injections, and follow-up times were also recorded from the institutional database. Data of the patients during previous treatment and novel treatment were compared. Results Forty patients were included in our study. Six patients who did not attend their controls and two patients who were observed to be non-compliant even though they presented to control visit were excluded from the study. The remaining 32 patients were enrolled in the study. The average treatment follow-up period of the patients was 6 (3-8) months. Fasting blood glucose (p = 0.014) and HbA1c (p = 0.004) values were significantly reduced after long-acting insulin analog therapy compared to the values during previous treatment. Similarly, total daily insulin dose was decreased after long-acting insulin analog treatment compared to the insulin dose before long-acting insulin analog treatment (p < 0.001). The decrease in the number of daily insulin injections after long-acting insulin analogs treatment compared to the number of injections before long-acting insulin analog treatment was statistically significant (p < 0.001). Conclusion We think that the addition of new long-acting insulin analogs to the treatment in patients with T2DM may be beneficial in achieving the target blood glucose, A1c, and may also be associated with treatment compliance.
Açıklama
Anahtar Kelimeler
Type 2 Diabetes Mellitus, Long-Acting Insulin Analogs, HbA1c, Fasting Plasma Glucose, Treatment, Basal
Kaynak
Journal of Public Health-Heidelberg
WoS Q Değeri
N/A
Scopus Q Değeri
N/A
Cilt
31
Sayı
12
Künye
Duman, T. T., Aktas, G., Tel, B. M. A., Bilgin, S., Kahveci, G., & Kurtkulagi, O. (2023). Evaluation of the effectiveness of long-acting insulin analogs in patients with type 2 diabetes mellitus. Journal of Public Health, 31(12), 2039-2044.
